- Home
- MYGN vs PSFE Comparison
MYGN vs PSFE Comparison
Compare MYGN & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PSFE
- Stock Information
- Founded
- MYGN 1991
- PSFE 1996
- Country
- MYGN United States
- PSFE United Kingdom
- Employees
- MYGN N/A
- PSFE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PSFE Business Services
- Sector
- MYGN Health Care
- PSFE Consumer Discretionary
- Exchange
- MYGN Nasdaq
- PSFE Nasdaq
- Market Cap
- MYGN 642.0M
- PSFE 770.1M
- IPO Year
- MYGN 1995
- PSFE N/A
- Fundamental
- Price
- MYGN $7.40
- PSFE $13.97
- Analyst Decision
- MYGN Hold
- PSFE Sell
- Analyst Count
- MYGN 13
- PSFE 4
- Target Price
- MYGN $13.50
- PSFE $17.38
- AVG Volume (30 Days)
- MYGN 1.3M
- PSFE 244.6K
- Earning Date
- MYGN 11-06-2025
- PSFE 11-12-2025
- Dividend Yield
- MYGN N/A
- PSFE N/A
- EPS Growth
- MYGN N/A
- PSFE N/A
- EPS
- MYGN N/A
- PSFE N/A
- Revenue
- MYGN $832,900,000.00
- PSFE $1,676,391,000.00
- Revenue This Year
- MYGN $0.17
- PSFE $3.18
- Revenue Next Year
- MYGN $6.19
- PSFE $7.05
- P/E Ratio
- MYGN N/A
- PSFE N/A
- Revenue Growth
- MYGN 3.83
- PSFE 0.47
- 52 Week Low
- MYGN $3.76
- PSFE $10.63
- 52 Week High
- MYGN $29.30
- PSFE $26.25
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- PSFE 52.72
- Support Level
- MYGN $7.13
- PSFE $13.77
- Resistance Level
- MYGN $7.80
- PSFE $14.45
- Average True Range (ATR)
- MYGN 0.44
- PSFE 0.51
- MACD
- MYGN 0.04
- PSFE -0.04
- Stochastic Oscillator
- MYGN 78.61
- PSFE 45.03
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.